Oppenheimer Ups BBOT Rating to Buy with $22 Price Target
Oppenheimer raised its rating on BBOT to buy, setting a $22 target, a 178.66% upside from the current price.
Key Points
- Oppenheimer raised its rating on BBOT to buy with a $22 price target on June 22, 2026.
- Oppenheimer's $22 price target implies 178.66% upside from BridgeBio Oncology Therapeutics, Inc.'s ($BBOT) current $7.89 share price.
- Shares of BBOT traded at $7.89 on Monday, reflecting investor interest following the new rating.
- Eventide Asset Management opened a new position in BBOT with 541,181 shares valued at $4.70 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Oppenheimer raised its rating on BBOT to a buy, setting a price target of $22. Analyst Mazahir Alimohamed made the call, highlighting confidence in the stock's potential. Shares of BBOT traded at $7.89 on Monday.
Oppenheimer vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in BBOT
Eventide Asset Management opened a new position in BBOT, acquiring 541,181 shares worth approximately $4.70 million. Avidity Partners Management also initiated a stake with 43,853 shares valued at $392,484. Accent Capital Management and Barclays PLC joined the list of new investors, adding 335 and 212 shares, valued at $2,998 and $1,897, respectively.
Analysts Set New Price Targets
On June 22, 2026, Oppenheimer assumed coverage of BBOT with a buy rating and a $22 price target. Earlier, on May 11, 2026, Canaccord Genuity initiated coverage with a buy rating and a $23 target. HC Wainwright & Co. maintained its buy rating with a $29 target on March 6, 2026. Other firms like Stifel and Raymond James have also recently initiated coverage with buy ratings and targets of $23 and $24, respectively.
Bottom Line
Oppenheimer's new buy rating and $22 target suggest optimism about BBOT's future prospects. Institutional interest, as seen with new positions from Eventide Asset Management and others, supports this view. Investors should remember that analysts' ratings and institutional moves are based on available data and projections, which can change over time.
Get BridgeBio Oncology Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBOT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.